Yunpeng Liu

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Peter M. Bruno, Yunpeng Liu, Ga Young Park et al. · Nature Medicine · 2017 · 525 citations · Full text

Life Sciences, Oncology, Pharmacology +14

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng et al. · Journal of Clinical Oncology · 2021 · 351 citations · Full text

Medicine, Oncology, Pharmacology +17

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lü, Jie Wang, Yan Yu et al. · Journal of Thoracic Oncology · 2021 · 278 citations · Full text

Medicine, Oncology, Pharmacology +17

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 254 citations

Medicine, Oncology, Pharmacotherapy +10